GBS Inc. to Present Third Quarter 2022 Financial Results and Recent Corporate Update on May 10
GBS Inc. will release its financial results for the third quarter ended March 31, 2022, on May 10, after the NASDAQ market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
GBS Inc. will release its financial results for the third quarter ended March 31, 2022, on May 10, after the NASDAQ market close. A conference call and webcast will be held at 4:30 p.m. ET to discuss these results. GBS specializes in developing non-invasive, real-time diagnostic tests, particularly for diabetes management using its innovative Biosensor Platform. Investors can access the live webcast through the company's website, with a replay available afterwards.
Positive
- Focus on real-time diagnostic testing for diabetes, indicating potential growth in a critical market.
Negative
- None.
Details
News Market Reaction – GBS
The recorded move for GBS in the trading session of this news was +1.74%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to Host Conference Call & Webcast at 4:30 p.m. ET
NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that it will release its financial results for the third quarter ended March 31, 2022, shortly after the NASDAQ market close on Tuesday, May 10. Management will then host a conference call and webcast at 4:30 p.m. ET.
| Title: | GBS Inc. Third Quarter 2022 Financial Results Conference Call & Webcast | ||
| Date: | Tuesday, May 10, 2022 | ||
| Time: | 4:30 p.m. ET | ||
| Conference Call Details: | Toll-Free: 855-327-6837 International: 631-891-4304 Conference ID: 10018968 | ||
| The conference call will be webcast live from the Company’s website and will be available via the following links: | |||
| Webcast: | Webcast Registration Link https://investors.gbs.inc/news-and-events/investor-calendar | ||
The webcast should be accessed 15 minutes prior to the conference call start time.
A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company’s website.
About GBS Inc.:
GBS Inc. is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. With the world-first Biosensor Platform, GBS Inc. is developing and launching diagnostic tests urgently needed to help people living with diabetes. For more information, please visit GBS.inc.
Company Contact:
Alex Arzeno – Vice President of IR & Communications
GBS, Inc.
Investor.Relations@gbs.inc
Investor Contact:
Tim McCarthy – Managing Director
LifeSci Advisors, LLC
Tim@LifeSciAdvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.